Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.

Yi, Huimei; Li, Ying; Tan, Yuan; Fu, Shujun; Tang, Faqing; Deng, Xiyun

Yi, Huimei; Li, Ying; Tan, Yuan; Fu, Shujun; Tang, Faqing; Deng, Xiyun.

Afiliação

Yi H; Key Laboratory of Translational Cancer Stem Cell Research, Hunan Normal University, Changsha, China.
Li Y; Departments of Pathology and Pathophysiology, Hunan Normal University School of Medicine, Changsha, China.
Tan Y; Key Laboratory of Translational Cancer Stem Cell Research, Hunan Normal University, Changsha, China.
Fu S; Departments of Pathology and Pathophysiology, Hunan Normal University School of Medicine, Changsha, China.
Tang F; Hunan Key Laboratory of Oncotarget Gene, Changsha, China.
Deng X; Department of Clinical Laboratory, Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Front Oncol ; 11: 648139, 2021.

Article em En | MEDLINE | ID: mdl-34094935

Palavras-chave

CTLA4; Immunotherapy; PD1/PDL1; immune checkpoint; triple-negative breast cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google